ALB and lobular neoplasia: Descriptive study comparing disease activity scores (renal BILAG scores), laboratory parameters (urine albumin / creatinine ratio, serum creatinine, ESR, anti-dsDNA antibody, C3 levels), physician global scores, time to achievement of inactive LN and subsequent flare at 4–8, 10–14 months post LN induction treatment initiation and last follow-up.  Standardized damage score (SLICC-SDI) compared at 10-14 months and last follow-up.